Send to

Choose Destination
Expert Opin Pharmacother. 2018 Mar;19(4):413-419. doi: 10.1080/14656566.2018.1444030. Epub 2018 Mar 7.

Glecaprevir + pibrentasvir for treatment of hepatitis C.

Author information

a Director of Hepatology, Assistant Professor of Medicine , Texas Tech University Health Sciences Center El Paso , El Paso , TX , USA.
b Chief, Gastroenterology and Hepatology, Professor of Medicine , University of Miami Miller School of Medicine , Miami , FL , USA.


Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such as advanced stage CKD or prior treatment failure to antiviral regimens containing other DAAs.


Antiviral therapy; direct-acting antiviral agents; hepatitis C; sustained virological response

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center